Tag: NASDAQ: SRNE

Business

Sorrento Therapeutics Inc (NASDAQ: SRNE) Gets EUA Endorsement and Import License From Mexico Authority COFEPRIS for COVI-STIX™

Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced that it has received Gets EUA Endorsement and Import License from Mexico Authority COFEPRIS for COVI-STIX™. COVI-STIX is a subtle and quick investigative examination for the uncovering of the SARS-CoV-2 disease. COFEPRIS delivered an Emergency Use Authorization (EUA) authorization and an import license […]

Business

Sorrento Therapeutics Inc (NASDAQ: SRNE) Proclaims Phase 2 Abivertinib Scientific Readings Have been Finished

Sorrento Therapeutics Inc (NASDAQ: SRNE) today broadcasted the conclusion of registration for its Phase 2 scientific pilot of Abivertinib in hospitalized COVID-19 patients in Brazil. This learning conclusion trails the lately finished registration of the U.S. Phase 2 scientific pilot. Statistics from the study is estimated to be accessible for […]

Business

Sorrento Therapeutics Inc. (NASDAQ: SRNE) Gains After MHRA Clears COVI-DROPS For Phase 2 Study

Sorrento Therapeutics Inc. (NASDAQ: SRNE) gained 1.6% after announcing the UK’s regulatory agency Medicines and Healthcare products Regulatory Agency cleared its COVI-DROPS candidate for a second phase efficacy study. MHRA clears Sorrento’s COVI-DROPS Application The company submitted the application as a rolling application with the MHRA clearing the trial within […]